Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data – PubMed

In the real world (outside of clinical trials), cardiovascular comorbidities really matter. Interesting article on the cardiovascular outcomes of patients treated with abiraterone and enzalutamide for men with mCRPC.

Read the full article here

Related Articles